Supplementary Figure S4 from First-in-Human Phase I/IIa Study of the First-in-Class CDK2/4/6 Inhibitor PF-06873600 Alone or with Endocrine Therapy in Patients with Breast Cancer

Key Points

• MAIN FINDING: The study evaluates a new CDK2/4/6 inhibitor's effect on tumor reduction in breast cancer patients.
• KEY EVIDENCE: Results showed changes in tumor size measured by the percent change from baseline, assessed using RECIST v1.1 criteria.
• APPROACH: The trial involved a full analysis set and examined both the inhibitor alone and in combination with endocrine therapy.
• SIGNIFICANCE: Findings could inform future treatments for breast cancer, highlighting a potential new option for therapy.